vs
Side-by-side financial comparison of BYLINE BANCORP, INC. (BY) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
BYLINE BANCORP, INC. is the larger business by last-quarter revenue ($112.4M vs $103.7M, roughly 1.1× Twist Bioscience Corp). BYLINE BANCORP, INC. runs the higher net margin — 33.4% vs -29.4%, a 62.9% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 9.0%).
Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
BY vs TWST — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $112.4M | $103.7M |
| Net Profit | $37.6M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | — | -31.7% |
| Net Margin | 33.4% | -29.4% |
| Revenue YoY | 9.0% | 16.9% |
| Net Profit YoY | 33.0% | 3.4% |
| EPS (diluted) | $0.83 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $103.7M | ||
| Q3 25 | $115.7M | — | ||
| Q2 25 | $110.5M | — | ||
| Q1 25 | $103.1M | — | ||
| Q4 24 | $104.7M | — | ||
| Q3 24 | $101.8M | — | ||
| Q2 24 | $99.4M | — |
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | $-30.5M | ||
| Q3 25 | $37.2M | — | ||
| Q2 25 | $30.1M | — | ||
| Q1 25 | $28.2M | — | ||
| Q4 24 | $30.3M | — | ||
| Q3 24 | $30.3M | — | ||
| Q2 24 | $29.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | -31.7% | ||
| Q3 25 | 43.1% | — | ||
| Q2 25 | 35.2% | — | ||
| Q1 25 | 36.4% | — | ||
| Q4 24 | 38.6% | — | ||
| Q3 24 | 39.3% | — | ||
| Q2 24 | 40.4% | — |
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | -29.4% | ||
| Q3 25 | 32.1% | — | ||
| Q2 25 | 27.2% | — | ||
| Q1 25 | 27.4% | — | ||
| Q4 24 | 34.3% | — | ||
| Q3 24 | 29.8% | — | ||
| Q2 24 | 29.9% | — |
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | $-0.50 | ||
| Q3 25 | $0.82 | — | ||
| Q2 25 | $0.66 | — | ||
| Q1 25 | $0.64 | — | ||
| Q4 24 | $0.68 | — | ||
| Q3 24 | $0.69 | — | ||
| Q2 24 | $0.68 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.4M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $456.1M |
| Total Assets | $9.9B | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $197.9M | ||
| Q3 25 | $259.0M | — | ||
| Q2 25 | $218.3M | — | ||
| Q1 25 | $421.3M | — | ||
| Q4 24 | $563.1M | — | ||
| Q3 24 | $452.6M | — | ||
| Q2 24 | $730.5M | — |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $456.1M | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $1.0B | — |
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $638.1M | ||
| Q3 25 | $9.8B | — | ||
| Q2 25 | $9.7B | — | ||
| Q1 25 | $9.6B | — | ||
| Q4 24 | $9.5B | — | ||
| Q3 24 | $9.4B | — | ||
| Q2 24 | $9.6B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $-24.8M | ||
| Q3 25 | $38.3M | — | ||
| Q2 25 | $16.3M | — | ||
| Q1 25 | $27.1M | — | ||
| Q4 24 | $175.2M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $40.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | $-34.8M | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $15.2M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $171.2M | — | ||
| Q3 24 | $19.1M | — | ||
| Q2 24 | $39.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | -33.5% | ||
| Q3 25 | 32.8% | — | ||
| Q2 25 | 13.7% | — | ||
| Q1 25 | 24.3% | — | ||
| Q4 24 | 163.5% | — | ||
| Q3 24 | 18.8% | — | ||
| Q2 24 | 39.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 9.6% | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 0.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 5.78× | — | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 1.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BY
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
